Afatinib and lung cancer

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30
   PubMed Web of Science ®Google Scholar
• Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993;342:19-21
   PubMed Web of Science ®Google Scholar
• Favaretto AG, Pasello G, Magro C. Second and third line treatment in advanced non-small cell lung cancer. Discov Med 2009;8:204-9
   PubMedGoogle Scholar
• Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103
   PubMed Web of Science ®Google Scholar
• Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-62
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97
   PubMed Web of Science ®Google Scholar
• Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-18
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012;13:300-8
   PubMed Web of Science ®Google Scholar
• Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013;14:981-8
   PubMed Web of Science ®Google Scholar
• Okano Y, Asami K, et al. Randomized phase III trial of erlotinib (E) versus docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who have wild-type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol 2013;31
   Google Scholar
• Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 2013;105:595-605
   PubMed Web of Science ®Google Scholar
• Baselga J. Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes. J Clin Oncol 2002;20:2217-19
   PubMed Web of Science ®Google Scholar
• Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58
   PubMed Web of Science ®Google Scholar
• Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-11
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500
   PubMed Web of Science ®Google Scholar
• Jura N, Endres NF, Engel K, et al. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 2009;137:1293-307
   PubMed Web of Science ®Google Scholar
• Endres NF, Das R, Smith AW, et al. Conformational coupling across the plasma membrane in activation of the EGF receptor. Cell 2013;152:543-56
   PubMed Web of Science ®Google Scholar
• Arkhipov A, Shan Y, Das R, et al. Architecture and membrane interactions of the EGF receptor. Cell 2013;152:557-69
   PubMed Web of Science ®Google Scholar
• Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81
   PubMed Web of Science ®Google Scholar
• Cooper WA, Lam DC, O’Toole SA, et al. Molecular biology of lung cancer. J Thorac Dis 2013;5:S479-90
   PubMedGoogle Scholar
• Bethune G, Bethune D, Ridgway N, et al. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis 2010;2:48-51
   PubMedGoogle Scholar
• Awada AH, Dumez H, Hendlisz A, et al. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors. Invest New Drugs 2013;31:734-41
   PubMed Web of Science ®Google Scholar
• Horn L, Lovly CM, et al. DIRECT: DNA-mutation inventory to refine and enhance cancer treatment –a catalogue of clinically relevant somatic mutations in lung cancer. J Clin Oncol 2011;29(suppl); abstract 7575
   Google Scholar
• Red Brewer M, Yun CH, Lai D, et al. Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. Proc Natl Acad Sci USA 2013;110:E3595-604
   PubMed Web of Science ®Google Scholar
• Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008;105:2070-5
   PubMed Web of Science ®Google Scholar
• Yun CH, Boggon TJ, Li Y, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007;11:217-27
   PubMed Web of Science ®Google Scholar
• He M, Capelletti M, Nafa K, et al. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res 2012;18:1790-7
   PubMedGoogle Scholar
• Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009;10:281-9
   PubMed Web of Science ®Google Scholar
• Ohashi K, Maruvka YE, Michor F, et al. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 2013;31:1070-80
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21:2237-46
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non–small-cell lung cancer. J Clin Oncol 2004;22:3238-47
   PubMed Web of Science ®Google Scholar
• Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer). Lancet 2005;366:1527-37
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57
   PubMed Web of Science ®Google Scholar
• Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012;343:342-50
   PubMed Web of Science ®Google Scholar
• Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702-11
   PubMed Web of Science ®Google Scholar
• Ninomiya T, Takigawa N, Ichihara E, et al. Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. Mol Cancer Ther 2013;12:589-97
   PubMed Web of Science ®Google Scholar
• Mazieres J, Peters S, Lepage B, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013;31:1997-2003
   PubMed Web of Science ®Google Scholar
• Perera SA, Li D, Shimamura T, et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci USA 2009;106:474-9
   PubMed Web of Science ®Google Scholar
• Regales L, Gong Y, Shen R, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009;119:3000-10
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Horn L, et al. Activity of afatinib/cetuximab in patients (pts) with EGFR mutant non small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors. Ann Oncol 2012;23; suppl; abstract 1227O
   PubMedGoogle Scholar
• Janjigian YY, Horn L, et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol 2011;29; suppl; abstract 7525
   Google Scholar
• Eskens FA, Mom CH, Planting AS, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 2008;98:80-5
   PubMed Web of Science ®Google Scholar
• Marshall J, Hwang J, Eskens FA, et al. A phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors. Invest New Drugs 2013;31:399-408
   PubMed Web of Science ®Google Scholar
• Yap TA, Vidal L, Adam J, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010;28:3965-72
   PubMed Web of Science ®Google Scholar
• Agus DB, Stopfer P, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours. J Clin Oncol 2006;24(suppl):abstract 2074
   Google Scholar
• Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012;13:528-38
   PubMed Web of Science ®Google Scholar
• Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010;28:357-60
   PubMed Web of Science ®Google Scholar
• Katakami N, Atagi S, Goto K, et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 2013;31:3335-41
   PubMed Web of Science ®Google Scholar
• Schuler MH, Park K, et al. Continuation of afatinib beyond progression: Results of a randomized, open-label, phase III trial of afatinib plus paclitaxel (P) versus investigator’s choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and afatinib–LUX-Lung 5 (LL5). J Clin Oncol 2014;32(5s(suppl):abstract 8019
   Google Scholar
• Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012;13:539-48
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-34
   PubMed Web of Science ®Google Scholar
• Wu YL ZC, Hu C-P, et al. LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. J Clin Oncol 2013(suppl):abstr 8016
   Google Scholar
• Yang JCH SL, Schuler MH, et al. Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT). J Clin Oncol 2014;32(5s):32
   Google Scholar
• Goss G, Felip E, et al. A randomized, open-label, phase III trial of afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: LUX-Lung 8 (LL8). ESMO abstract # 12220 2014
   Google Scholar
• Yang JC, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3342-50
   PubMed Web of Science ®Google Scholar
• Hirsh V, Cadranel J, Cong XJ, et al. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). J Thorac Oncol 2013;8:229-37
   PubMed Web of Science ®Google Scholar
• Afatinib expanded access program. Available from: http://clinicaltrials.gov/show/NCT01649284
   Google Scholar
• Kato T, Nishio M, et al. Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial. J Clin Oncol 2014;32(suppl):abstract 8005
   Google Scholar
• A study of intermittent, high-dose afatinib to determine the maximal tolerated dose and assess activity of this dose against non-small cell lung cancer with T790M mutations. Available from: www.clinicaltrials.gov/show/NCT01647711
   Google Scholar
• Adjuvant afatinib in stage I-III NSCLC with EGFR mutation. Available from: http://clinicaltrials.gov/show/NCT01746251
   Google Scholar
• Afatinib with CT and RT for EGFR-mutant NSCLC. Available from: http://clinicaltrials.gov/show/NCT01553942
   Google Scholar
• ADAM-afatinib diarrhea assessment and management. Available from: http://clinicaltrials.gov/show/NCT01814553
   Google Scholar
• Efficacy and safety study of BIBW 2992 to treat lung cancer patients (TIMELY). Available from: http://clinicaltrials.gov/show/NCT01415011
   Google Scholar
• Deciphering afatinib response and resistance with intratumour heterogeneity (DARWIN1). Available from: http://clinicaltrials.gov/show/NCT02183883
   Google Scholar
• Afatinib plus nimotuzumb for NSCLC. Available from: http://clinicaltrials.gov/show/NCT01861223
   Google Scholar
• Phase I study of the combination of afatinib and ruxolitinib in patients with treatment-refractory non-small cell lung cancer (NSCLC). Available from: http://clinicaltrials.gov/show/NCT02145637
   Google Scholar
• Phase I trial of afatinib (BIBW 2992) and dasatinib in non-small cell lung cancer (NSCLC). Available from: http://clinicaltrials.gov/show/NCT01999985
   Google Scholar
• BI 836845 plus afatinib in patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). Available from: http://clinicaltrials.gov/show/NCT02191891
   Google Scholar
• LUX-Lung 7: a phase IIb trial of afatinib(BIBW2992) versus gefitinib for the treatment of 1st line EGFR mutation positive adenocarcinoma of the lung. Available from: http://clinicaltrials.gov/show/ NCT01466660
   Google Scholar